Células madre y Derivados
Los inhibidores de células madre son compuestos que se dirigen específicamente a las vías de señalización y proteínas involucradas en el mantenimiento, diferenciación y proliferación de células madre. Estos inhibidores son cruciales para comprender la biología de las células madre y para desarrollar estrategias que permitan manipularlas con fines terapéuticos, como en la medicina regenerativa y el tratamiento del cáncer. Al controlar el destino de las células madre, estos inhibidores pueden ayudar a guiar la diferenciación de células madre en tipos celulares específicos o prevenir el crecimiento celular no deseado. En CymitQuimica, ofrecemos una selección de inhibidores de células madre de alta calidad para apoyar su investigación en biología de células madre, biología del desarrollo y medicina regenerativa.
Subcategorías de "Células madre y Derivados"
- Gamma-secretasa(59 productos)
- Hedgehog / Smoothened(44 productos)
- Hippo pathway(6 productos)
- JAK(245 productos)
- Porcupine (Puerco espín)(9 productos)
- ROCK(70 productos)
- STAT(98 productos)
- Células madre(486 productos)
- TGF-beta / Smad(58 productos)
- Wnt / beta-catenina(66 productos)
Mostrar 2 subcategorías más
Se han encontrado 695 productos de "Células madre y Derivados"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ROCK-IN-1
CAS:<p>ROCK-IN-1 is a potent ROCK inhibitor that inhibits ROCK2-mediated signaling with an IC50 value of 1.2 nM.ROCK-IN-1 can be used in the study of neurological</p>Fórmula:C20H18FN3OPureza:>99.99%Forma y color:SolidPeso molecular:335.37JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Fórmula:C18H20N4O3Pureza:98.04% - 98.19%Forma y color:SolidPeso molecular:340.38GSK-3 inhibitor 1
CAS:<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Fórmula:C22H17ClFN5O2Pureza:98.42%Forma y color:SolidPeso molecular:437.85PT109
CAS:<p>PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.</p>Fórmula:C23H31N3OS2Forma y color:SolidPeso molecular:429.64LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Fórmula:C26H31N7O2Forma y color:SolidPeso molecular:473.57Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Fórmula:C20H20N4O2SForma y color:SolidPeso molecular:380.463JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Fórmula:C22H17FN6O2SPureza:98%Forma y color:SolidPeso molecular:448.47JAK3-IN-11
CAS:<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Fórmula:C23H23N5O2Forma y color:SolidPeso molecular:401.46M3686
CAS:<p>M3686 (Compound 29) is a potent and selective TEAD1 inhibitor with an IC50 value of 51 nM. It exhibits weaker binding activity toward TEAD3. M3686 significantly inhibits the cellular activity of YAP-dependent NCI-H226 cell lines, with an IC50 value of 0.06 μM, and demonstrates strong antitumor effects in the NCI-H226 xenograft model.</p>Fórmula:C21H18F3N5O2Forma y color:SolidPeso molecular:429.395lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Fórmula:C16H25N5OSForma y color:SolidPeso molecular:335.468TEAD-IN-10
CAS:<p>TEAD-IN-10 (compound 15), a covalent inhibitor, exhibits selective and potent inhibitory activity against TEAD1 (IC 50 =14 nM), TEAD2 (IC 50 =179 nM), and TEAD3 (IC 50 =4 nM). This compound is utilized in cancer research [1].</p>Fórmula:C15H14F3NOForma y color:SolidPeso molecular:281.27Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Fórmula:C21H25F2N7OForma y color:SolidPeso molecular:429.47TEAD-IN-1
CAS:<p>TEAD-IN-1 (Compound 2) is an effective inhibitor of TEAD auto-palmitoylation with an IC50 of 603 nM. It enhances the interaction between TEAD and VGLL4, while diminishing the interaction between YAP and TEAD. TEAD-IN-1 is applicable for cancer research.</p>Fórmula:C15H20F2N2O3SForma y color:SolidPeso molecular:346.393YAP/TAZ inhibitor-3
CAS:<p>YAP/TAZ inhibitor-3 (Compound 24) is a YAP/TAZ inhibitor applicable for relevant research within the life sciences field.</p>Fórmula:C21H18F3NO3Pureza:99.63%Forma y color:SolidPeso molecular:389.37(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.42Londamocitinib
CAS:<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Fórmula:C28H31F2N7O4SPureza:98.64% - 99.56%Forma y color:SolidPeso molecular:599.65CDK8-IN-11
CAS:<p>CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.</p>Fórmula:C19H15F3N4O2Pureza:99.74%Forma y color:SolidPeso molecular:388.34JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Fórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Fórmula:C25H24N6O3S2Pureza:98%Forma y color:SolidPeso molecular:520.63WZ-2-033
CAS:<p>WZ-2-033 is a potent STAT3 inhibitor. It inhibits proliferation, colony survival, migration, and invasion of MDA-MB-231, HCC70, and MDA-MB231-4175 cells, with IC50 values of 0.7, 1.3, and 1.3 μM respectively.</p>Fórmula:C25H18F3N3O4SForma y color:SolidPeso molecular:513.49STAT3-IN-8
CAS:<p>"STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1]."</p>Fórmula:C19H7F7N2O3Pureza:98%Forma y color:SolidPeso molecular:444.26PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Forma y color:SolidPeso molecular:566.63PF-06648671
CAS:<p>PF-06648671 is a γ-secretase modulator for the treatment of neurodegenerative and/or neurological disorders.</p>Fórmula:C25H23ClF4N4O3Pureza:98%Forma y color:SolidPeso molecular:538.92TGFβ1-IN-1
CAS:<p>TGFβ1-IN-1 is a TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in cancer research.</p>Fórmula:C22H24N2O3Pureza:99.89% - 99.89%Forma y color:SolidPeso molecular:364.438GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Fórmula:C22H21N5O2SForma y color:SolidPeso molecular:419.50HDAC6-IN-9
CAS:<p>HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.</p>Fórmula:C19H16N2O3Pureza:98.84%Forma y color:SolidPeso molecular:320.34DAPM
CAS:<p>DAPM (gamma-Secretase Inhibitor XVI) is a Notch pathway inhibitor with anticancer activity and antiproliferative effects.</p>Fórmula:C20H20F2N2O4Pureza:99.76%Forma y color:SolidPeso molecular:390.38Aβ42-IN-1
CAS:<p>Aβ42-IN-1, compound 1v, is a novel, potent and orally active γ-secretase modulator (GSM).</p>Fórmula:C29H27ClN4O2Pureza:98%Forma y color:SolidPeso molecular:499Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Fórmula:C24H25N7O2Forma y color:SolidPeso molecular:443.50TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Forma y color:SolidPeso molecular:489.458TEAD-IN-20
CAS:<p>TEAD-IN-20 is a TEAD inhibitor with IC50 values of 0.021 μM in TEAD4 FRET and 0.044 μM in TEAD4 MCF7-Tead cell lines. It has potential applications in cancer research.</p>Fórmula:C20H19F3N4O3Forma y color:SolidPeso molecular:420.39JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Fórmula:C26H36FN5O2Forma y color:SolidPeso molecular:469.59iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Fórmula:C19H15F3N2O2Forma y color:SolidPeso molecular:360.33CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Fórmula:C18H16ClN5OForma y color:SolidPeso molecular:353.806Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Fórmula:C19H19F2N7O3Forma y color:SolidPeso molecular:431.40(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Fórmula:C20H27ClN6OForma y color:SolidPeso molecular:402.92Carboxylesterase-IN-3
CAS:<p>Carboxylesterase-IN-3 is a potent inhibitor of Carboxylesterase Notum (IC50 ≤ 10 nM).Carboxylesterase-IN-3 has the potential to study cancer diseases.</p>Fórmula:C11H6Cl2N4OSPureza:97.49% - 98.47%Forma y color:SolidPeso molecular:313.16STAT3-IN-35
CAS:<p>STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.</p>Fórmula:C21H23NO4Forma y color:SolidPeso molecular:353.41YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Fórmula:C17H23N7OForma y color:SolidPeso molecular:341.41YAP/TAZ-TEAD-IN-2
<p>YAP/TAZ-TEAD-IN-2 (Compound 51) is a YAP/TAZ-TEAD inhibitor that disrupts the interaction between YAP/TAZ and TEAD. It inhibits the transcriptional activity of TEAD with an IC50 of 1.2 nM. Additionally, YAP/TAZ-TEAD-IN-2 suppresses the expression of target genes (Cyr61, CTGF, AXL, and Survivin) and the proliferation of breast cancer cells.</p>Fórmula:C19H20N2O3SForma y color:SolidPeso molecular:356.44JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Fórmula:C31H31F3N8O4Forma y color:SolidPeso molecular:639.64JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Fórmula:C16H13IN6Forma y color:SolidPeso molecular:416.22AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H14FN5OForma y color:SolidPeso molecular:323.32PMMB-187
CAS:<p>PMMB-187, a selective STAT3 inhibitor, exhibits an IC50 of 1.81 μM in MDA-MB-231 cells. This compound induces apoptosis in MDA-MB-231 cells by inhibiting STAT3 transcriptional activity and nuclear translocation, reducing mitochondrial membrane potential, increasing reactive oxygen species (ROS) production, and upregulating the expression of apoptosis-related proteins. PMMB-187 is useful for research in the field of cancer.</p>Fórmula:C27H23BrN2O6S2Forma y color:SolidPeso molecular:615.52JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Forma y color:SolidJAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Fórmula:C20H15ClF3N3OSForma y color:SolidPeso molecular:437.87AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H13ClFN5OForma y color:SolidPeso molecular:357.77JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62
